Reply to The 5-year relative survival of older patients with prostate cancer is insignificantly different from the 5-year survival of all men of a similar age
- PMID: 32073647
- DOI: 10.1002/cncr.32791
Reply to The 5-year relative survival of older patients with prostate cancer is insignificantly different from the 5-year survival of all men of a similar age
Comment on
-
Age dependence of modern clinical risk groups for localized prostate cancer-A population-based study.Cancer. 2020 Apr 15;126(8):1691-1699. doi: 10.1002/cncr.32702. Epub 2020 Jan 3. Cancer. 2020. PMID: 31899813 Free PMC article.
-
The 5-year relative survival of older patients with prostate cancer is insignificantly different from the 5-year survival of all men of a similar age.Cancer. 2020 Jun 1;126(11):2718. doi: 10.1002/cncr.32788. Epub 2020 Feb 19. Cancer. 2020. PMID: 32073649 Free PMC article. No abstract available.
References
-
- Huynh-Le MP, Myklebust TA, Feng CH, et al. Age dependence of modern clinical risk groups for localized prostate cancer-a population-based study. Cancer. Published online January 3, 2020. doi:10.1002/cncr.32702
-
- Mariotto AB, Noone AM, Howlader N, et al. Cancer survival: an overview of measures, uses, and interpretation. J Natl Cancer Inst Monogr. 2014;2014:145-186.
-
- Mathers MJ, Roth S, Klinkhammer-Schalke M, et al. Patients with localised prostate cancer (t1-t2) show improved overall long-term survival compared to the normal population. J Cancer. 2011;2:76-80.
-
- Spratt DE, Zhang J, Santiago-Jimenez M, et al. Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer. J Clin Oncol. 2018;36:581-590.
-
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 4. 2019. Accessed January 2, 2020. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical